FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Vaccine2006; 25(30); 5606-5612; doi: 10.1016/j.vaccine.2006.11.066

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.

Abstract: The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized.
Get Full Text
Publication Date: 2006-12-08 PubMed ID: 17227690DOI: 10.1016/j.vaccine.2006.11.066Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses the use of canarypox vaccine vector (ALVAC) to develop and procure multiple vaccines for domestic and equine animals in Europe and the U.S. The article emphasizes the importance of understanding both the biology of the vector and the recombinant virus to ensure its safety, as well as the need for extensive trials before it is approved for use.

Canarypox Vaccine Vector (ALVAC)

  • The research paper discusses the characteristics of the ALVAC, a canarypox vaccine vector utilized for developing different vaccines. It notes its ubiquity, high safety margin, and the structural and genetic stability of this technology.
  • ALVAC is noted as non-replicative in mammals, which contributes to its safety profile. Its ability to elicit both humoral (antibody-mediated) and cell-mediated immune responses is also highlighted, signifying its effectiveness in inducing immunity against diseases.

Development and Registration of Vaccines

  • The study underscores the inherent regulations in the development and registration of recombinant vector vaccines, emphasizing the sector’s stringent procedures.
  • The research underscores the importance of comprehensive knowledge about the vector biology as well as the recombinant virus. Understanding these entities aids in assessing the potential risks associated with its use in the identified species.

Risk Assessment and Trials

  • The paper emphasizes the need for comprehensive risk assessment before the recombinant vector vaccines’ use. Fundamentally, the safety of the host and the environmental impact must be extensively evaluated.
  • The research stresses the importance of extensive demonstration of its safety. For a recombinant vector vaccine to be authorized for field trials, its safety must undergo rigorous assessment and verification processes.

Cite This Article

APA
Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC. (2006). Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine, 25(30), 5606-5612. https://doi.org/10.1016/j.vaccine.2006.11.066

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 25
Issue: 30
Pages: 5606-5612

Researcher Affiliations

Poulet, Hervé
  • Merial SAS, 254, rue Marcel Mérieux, 69007 Lyon, France. herve.poulet@merial.com
Minke, Jules
    Pardo, Maria Camila
      Juillard, Véronique
        Nordgren, Bob
          Audonnet, Jean-Christophe

            MeSH Terms

            • Animals
            • Canarypox virus / genetics
            • Drug Approval
            • Genetic Vectors / genetics
            • Vaccines, Synthetic / adverse effects
            • Vaccines, Synthetic / genetics
            • Vaccines, Synthetic / therapeutic use
            • Viral Vaccines / adverse effects
            • Viral Vaccines / genetics
            • Viral Vaccines / therapeutic use

            Citations

            This article has been cited 32 times.
            1. Zhang Y, Mo R, Sun S, Cui Z, Liang B, Li E, Wang T, Feng Y, Yang S, Yan F, Zhao Y, Xia X. Bacillus subtilis vector based oral rabies vaccines induced potent immune response and protective efficacy in mice. Front Microbiol 2023;14:1126533.
              doi: 10.3389/fmicb.2023.1126533pubmed: 36846792google scholar: lookup
            2. El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines (Basel) 2022 May 26;10(6).
              doi: 10.3390/vaccines10060855pubmed: 35746463google scholar: lookup
            3. Unger H, Kangethe RT, Liaqat F, Viljoen GJ. Advances in Irradiated Livestock Vaccine Research and Production Addressing the Unmet Needs for Farmers and Veterinary Services in FAO/IAEA Member States. Front Immunol 2022;13:853874.
              doi: 10.3389/fimmu.2022.853874pubmed: 35418985google scholar: lookup
            4. Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study. J Vet Intern Med 2022 May;36(3):1179-1184.
              doi: 10.1111/jvim.16425pubmed: 35416353google scholar: lookup
            5. Nurzijah I, Elbohy OA, Kanyuka K, Daly JM, Dunham S. Development of Plant-Based Vaccines for Prevention of Avian Influenza and Newcastle Disease in Poultry. Vaccines (Basel) 2022 Mar 19;10(3).
              doi: 10.3390/vaccines10030478pubmed: 35335110google scholar: lookup
            6. Lemon JL, McMenamy MJ. A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease. Vaccines (Basel) 2021 Nov 27;9(12).
              doi: 10.3390/vaccines9121403pubmed: 34960149google scholar: lookup
            7. Cid R, Bolívar J. Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules 2021 Jul 21;11(8).
              doi: 10.3390/biom11081072pubmed: 34439738google scholar: lookup
            8. Margolin E, Burgers WA, Sturrock ED, Mendelson M, Chapman R, Douglass N, Williamson AL, Rybicki EP. Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. Nat Rev Microbiol 2020 Dec;18(12):690-704.
              doi: 10.1038/s41579-020-00441-3pubmed: 32913297google scholar: lookup
            9. Sharma C, Rokana N, Chandra M, Singh BP, Gulhane RD, Gill JPS, Ray P, Puniya AK, Panwar H. Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals. Front Vet Sci 2017;4:237.
              doi: 10.3389/fvets.2017.00237pubmed: 29359135google scholar: lookup
            10. Guillaume-Vasselin V, Lemaitre L, Dhondt KP, Tedeschi L, Poulard A, Charreyre C, Horvat B. Protection from Hendra virus infection with Canarypox recombinant vaccine. NPJ Vaccines 2016;1:16003.
              doi: 10.1038/npjvaccines.2016.3pubmed: 29263849google scholar: lookup
            11. Francis MJ. Recent Advances in Vaccine Technologies. Vet Clin North Am Small Anim Pract 2018 Mar;48(2):231-241.
              doi: 10.1016/j.cvsm.2017.10.002pubmed: 29217317google scholar: lookup
            12. McCoy CR, Jackson NL, Day J, Clinton SM. Genetic predisposition to high anxiety- and depression-like behavior coincides with diminished DNA methylation in the adult rat amygdala. Behav Brain Res 2017 Mar 1;320:165-178.
              doi: 10.1016/j.bbr.2016.12.008pubmed: 27965039google scholar: lookup
            13. Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy 2015;7(12):1249-58.
              doi: 10.2217/imt.15.90pubmed: 26595180google scholar: lookup
            14. Deng S, Martin C, Patil R, Zhu F, Zhao B, Xiang Z, He Y. Vaxvec: The first web-based recombinant vaccine vector database and its data analysis. Vaccine 2015 Nov 27;33(48):6938-46.
              doi: 10.1016/j.vaccine.2015.07.113pubmed: 26403370google scholar: lookup
            15. Loomis RJ, Johnson PR. Emerging Vaccine Technologies. Vaccines (Basel) 2015 May 26;3(2):429-47.
              doi: 10.3390/vaccines3020429pubmed: 26343196google scholar: lookup
            16. Zanetti FA, Grand MD, Mitarotonda RC, Taboga OA, Calamante G. Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens. Braz J Microbiol 2014;45(1):231-4.
              doi: 10.1590/s1517-83822014000100032pubmed: 24948937google scholar: lookup
            17. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med 2014 Jun;6(6):708-20.
              doi: 10.1002/emmm.201403876pubmed: 24803000google scholar: lookup
            18. Angenvoort J, Fischer D, Fast C, Ziegler U, Eiden M, de la Fuente JG, Lierz M, Groschup MH. Limited efficacy of West Nile virus vaccines in large falcons (Falco spp.). Vet Res 2014 Apr 7;45(1):41.
              doi: 10.1186/1297-9716-45-41pubmed: 24708385google scholar: lookup
            19. Draper SJ, Cottingham MG, Gilbert SC. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 2013 Sep 6;31(39):4223-30.
              doi: 10.1016/j.vaccine.2013.05.091pubmed: 23746455google scholar: lookup
            20. Yang DK, Kim HH, Lee KW, Song JY. The present and future of rabies vaccine in animals. Clin Exp Vaccine Res 2013 Jan;2(1):19-25.
              doi: 10.7774/cevr.2013.2.1.19pubmed: 23596586google scholar: lookup
            21. Koppers-Lalic D, Hoeben RC. Non-human viruses developed as therapeutic agent for use in humans. Rev Med Virol 2011 Jul;21(4):227-39.
              doi: 10.1002/rmv.694pubmed: 21560181google scholar: lookup
            22. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010 Jan;8(1):62-73.
              doi: 10.1038/nrmicro2240pubmed: 19966816google scholar: lookup
            23. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, Wong S, Huynh T, Baskin CR. Vaccinia virus vaccines: past, present and future. Antiviral Res 2009 Oct;84(1):1-13.
              doi: 10.1016/j.antiviral.2009.06.006pubmed: 19563829google scholar: lookup
            24. Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B, Davis-Poynter N, Wood J, Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 2009 Jun 22;4(6):e5997.
              doi: 10.1371/journal.pone.0005997pubmed: 19543394google scholar: lookup
            25. Hu N, Yu R, Shikuma C, Shiramizu B, Ostrwoski MA, Yu Q. Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells. Vaccine 2009 May 14;27(22):2994-3006.
              doi: 10.1016/j.vaccine.2009.02.103pubmed: 19428911google scholar: lookup
            26. Rao SS, Styles D, Kong W, Andrews C, Gorres JP, Nabel GJ. A gene-based avian influenza vaccine in poultry. Poult Sci 2009 Apr;88(4):860-6.
              doi: 10.3382/ps.2008-00360pubmed: 19276436google scholar: lookup
            27. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, Keil GM, Klonjkowski B, Le Potier MF, Libeau G, Ortego J, Richardson J, Takamatsu HH. Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2008 Dec 2;26(51):6508-28.
              doi: 10.1016/j.vaccine.2008.09.044pubmed: 18838097google scholar: lookup
            28. Harenberg A, Guillaume F, Ryan EJ, Burdin N, Spada F. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine 2008 Sep 15;26(39):5004-13.
              doi: 10.1016/j.vaccine.2008.07.050pubmed: 18691624google scholar: lookup
            29. Fehlner-Gardiner C, Gongal G, Tenzin T, Sabeta C, De Benedictis P, Rocha SM, Vargas A, Cediel-Becerra N, Gomez LC, Maki J, Rupprecht CE. Rabies in Cats-An Emerging Public Health Issue. Viruses 2024 Oct 19;16(10).
              doi: 10.3390/v16101635pubmed: 39459967google scholar: lookup
            30. Jogi HR, Smaraki N, Rajak KK, Yadav AK, Bhatt M, Einstien C, Revathi A, Thakur R, Kamothi DJ, Dedeepya PVSS, Savsani HH. Revolutionizing Veterinary Health with Viral Vector-Based Vaccines. Indian J Microbiol 2024 Sep;64(3):867-878.
              doi: 10.1007/s12088-024-01341-3pubmed: 39282171google scholar: lookup
            31. Weidinger AK, Bergmann M, König M, Zablotski Y, Hartmann K. Anti-rabies humoral immune response in cats after concurrent vs separate vaccination against rabies and feline leukaemia virus using canarypox-vectored vaccines. J Feline Med Surg 2024 Feb;26(2):1098612X231218643.
              doi: 10.1177/1098612X231218643pubmed: 38358295google scholar: lookup
            32. Volkmann A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, Excler JL, Condit RC, Evans E, Smith ER, Kim D, Chen RT. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine 2021 May 21;39(22):3067-3080.
              doi: 10.1016/j.vaccine.2020.08.050pubmed: 33077299google scholar: lookup
            Subscribe to our newsletter
            Join 99,970 horse owners like you who receive our email updates on horse health and nutrition.